Pharmacogenetic effects of 'candidate gene complexes' on stroke in the GenHAT study

Pharmacogenetics and Genomics

Volumn 24, Issue 11, 2014, Pages 556-563

  Sorensen, Izel F ^a   Vazquez, Ana I ^a   Irvin, Marguerite R ^a   Sorensen, Peter ^d   Davis, Barry R ^b   Ford, Charles E ^b   Boerwinkle, Eric ^b   Eckfeldt, John H ^c   Arnett, Donna K ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d AARHUS UNIVERSITY   (Denmark)

Author keywords

Antihypertensive treatment; GenHAT; genotype by treatment interaction; stroke

Indexed keywords

AMLODIPINE; CHLORTALIDONE; LISINOPRIL;

AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; FEMALE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SINGLE NUCLEOTIDE POLYMORPHISM; GENETICS; MIDDLE AGED; STROKE;

AGED; AMLODIPINE; CHLORTHALIDONE; FEMALE; GENOTYPE; HUMANS; LISINOPRIL; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; STROKE;

EID: 84930172735     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0000000000000088     Document Type: Article

References (47)

1. Yoon SS, Otschega Y, Louis T. Recent trends in the prevalence of high blood pressure and its treatment and control, 1999-2008. Hyattsville, MD: US Department of Health and Human Services, CDC, National Center for Health Statistics; 2010.
2. National Heart, Lung, and Blood Institute. Chart 3-67. Morbidity and mortality: 2009 chart book on cardiovascular, lung and blood diseases. Rockville, MD: US Department of Health and Human Services, National Institutes of Health; 2009. 54:p. 114.
3. Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003; 289:2363-2369.
4. Joffres M, Falaschetti E, Gillespie C, Robitaille C, Loustalot F, Poulter N, et al. Hypertension prevalence, awareness, treatment and control in national surveys from England, the USA and Canada, and correlation with stroke and ischaemic heart disease mortality: a cross-sectional study. BMJ Open 2013; 3:e003423.
5. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2014 update: a report from the American Heart Association. Circulation 2014; 129:e28-e292.
6. Nichols M, Townsend N, Luengo-Fernandez R, Leal J, Gray A, Scarborough P, et al. Table 1.1. European Cardiovascular Disease Statistics 2012. Brussels, Sophia Antipolis: European Heart Network, European Society of Cardiology; 2012.
7. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000; 356:1955-1964.
8. Gillespie C, Kuklina EV, Briss PA, Blair NA, Hong Y. Division for Heart Disease and Stroke Prevention, National Center for Chronic Disease Prevention and Health Promotion, CDC. Vital Signs: Prevalence, Treatment, and Control of Hypertension - United States, 1999-2002 and 2005-2008. Circulation 2011; 123:933-944.
9. Ma J, Stafford RS. Screening, treatment, and control of hypertension in US private physician offices, 2003-2004. Hypertension 2008; 51:1275-1281.
10. Mori H, Ukai H, Yamamoto H, Saitou S, Hirao K, Yamauchi M, Umemura S. Current status of antihypertensive prescription and associated blood pressure control in Japan. Hypertens Res 2006; 29:143-151.
11. Rodríguez-Roca GC, Pallarés-Carratalá V, Alonso-Moreno FJ, Escobar-Cervantes C, Barrios V, Llisterri JL, et al. Working group of arterial hypertension of the Spanish Society of Primary Care physicians (Group HTA/SEMERGEN); PRESCAP 2006 investigators. Blood pressure control and physicians' therapeutic behavior in a very elderly Spanish hypertensive population. Hypertens Res 2009; 32:753-758.
12. Thoenes M, Neuberger HR, Volpe M, Khan BV, Kirch W, Böhm M. Antihypertensive drug therapy and blood pressure control in men and women: an international perspective. J Hum Hypertens 2010; 24:336-344.
13. Ferrari P, Bianchi G. Genetic mapping and tailored antihypertensive therapy. Cardiovasc Drugs Ther 2000; 14:387-395.
14. Johnson JA. Advancing management of hypertension through pharmacogenomics. Ann Med 2012; 44 (Suppl 1):S17-S22.
15. Navis G, Bakker SJ, van der Harst P. Dissecting the genetics of complex traits: lessons from hypertension. Nephrol Dial Transplant 2010; 25:1382-1385.
16. Hottenga JJ, Whitfield JB, de Geus EJ, Boomsma DI, Martin NG. Heritability and stability of resting blood pressure in Australian twins. Twin Res Hum Genet 2006; 9:205-209.
17. Newton-Cheh C, Johnson T, Gateva V, Tobin MD, Bochud M, Coin L, et al. Wellcome Trust Case Control Consortium. Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet 2009; 41:666-676.
18. Lango Allen H, Estrada K, Lettre G, Berndt SI, Weedon MN, Rivadeneira F, et al. Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature 2010; 467:832-838.
19. Maurano MT, Humbert R, Rynes E, Thurman RE, Haugen E, Wang H, et al. Systematic localization of common disease-associated variation in regulatory DNA. Science 2012; 337:1190-1195.
20. Lage K, Greenway SC, Rosenfeld JA, Wakimoto H, Gorham JM, Segrè AV, et al. Genetic and environmental risk factors in congenital heart disease functionally converge in protein networks driving heart development. Proc Natl Acad Sci U S A 2012; 109:14035-14040.
21. O'Roak BJ, Vives L, Girirajan S, Karakoc E, Krumm N, Coe BP, et al. Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. Nature 2012; 485:246-250.
22. Arnett DK, Boerwinkle E, Davis BR, Eckfeldt J, Ford CE, Black H. Pharmacogenetic approaches to hypertension therapy: design and rationale for the Genetics of Hypertension Associated Treatment (GenHAT) study. Pharmacogenomics J 2002; 2:309-317.
23. Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright JT Jr, Cushman WC, et al. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group. Am J Hypertens 1996; 9:342-360.
24. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000; 283:1967-1975.
25. National Heart, Lung, and Blood Institute. NHLBI report of the special emphasis panel on opportunities and obstacles to genetic research in NHLBI clinical studies. Bethesda, MD: National Heart, Lung, and Blood Institute, NIH; 1997.
26. Lynch AI, Irvin MR, Boerwinkle E, Davis BR, Vaughan LK, Ford CE, et al. RYR3 gene polymorphisms and cardiovascular disease outcomes in the context of antihypertensive treatment. Pharmacogenomics J 2013; 13:330-334.
27. Little J, Sharp L, Khoury MJ, Bradley L, Gwinn M. The epidemiologic approach to pharmacogenomics. Am J Pharmacogenomics 2005; 5:1-20.
28. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 1995; 57:289-300.
29. Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, Roth A, et al. STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res 2013; 41:D808-D815.
30. Eijgelsheim M, Aarnoudse AL, Rivadeneira F, Kors JA, Witteman JC, Hofman A, et al. Identification of a common variant at the NOS1AP locus strongly associated to QT-interval duration. Hum Mol Genet 2009; 18:347-357.
31. Soliman EZ, Howard G, Cushman M, Kissela B, Kleindorfer D, Le A, et al. Prolongation of QTc and risk of stroke: The REGARDS (REasons for Geographic and Racial Differences in Stroke) study. J Am Coll Cardiol 2012; 59:1460-1467.
32. Aarnoudse AJ, Newton-Cheh C, de Bakker PI, Straus SM, Kors JA, Hofman A, et al. Common NOS1AP variants are associated with a prolonged QTc interval in the Rotterdam Study. Circulation 2007; 116:10-16.
33. Post W, Shen H, Damcott C, Arking DE, Kao WH, Sack PA, et al. Associations between genetic variants in the NOS1AP (CAPON) gene and cardiac repolarization in the old order Amish. Hum Hered 2007; 64:214-219.
34. Kao WH, Arking DE, Post W, Rea TD, Sotoodehnia N, Prineas RJ, et al. Genetic variations in nitric oxide synthase 1 adaptor protein are associated with sudden cardiac death in US white community-based populations. Circulation 2009; 119:940-951.
35. Lehtinen AB, Newton-Cheh C, Ziegler JT, Langefeld CD, Freedman BI, Daniel KR, et al. Association of NOS1AP genetic variants with QT interval duration in families from the Diabetes Heart Study. Diabetes 2008; 57:1108-1114.
36. Raitakari OT, Blom-Nyholm J, Koskinen TA, Kähönen M, Viikari JS, Lehtimäki T. Common variation in NOS1AP and KCNH2 genes and QT interval duration in young adults. The Cardiovascular Risk in Young Finns Study. Ann Med 2009; 41:144-151.
37. Arking DE, Pfeufer A, Post W, Kao WH, Newton-Cheh C, Ikeda M, et al. A common genetic variant in the NOS1 regulator NOS1AP modulates cardiac repolarization. Nat Genet 2006; 38:644-651.
38. Ikram MA, Seshadri S, Bis JC, Fornage M, DeStefano AL, Aulchenko YS, et al. Genomewide association studies of stroke. N Engl J Med 2009; 360:1718-1728.
39. Araki T, Milbrandt J. Ninjurin2, a novel homophilic adhesion molecule, is expressed in mature sensory and enteric neurons and promotes neurite outgrowth. J Neurosci 2000; 20:187-195.
40. Smith NL, Felix JF, Morrison AC, Demissie S, Glazer NL, Loehr LR, et al. Association of genome-wide variation with the risk of incident heart failure in adults of European and African ancestry: a prospective meta-analysis from the cohorts for heart and aging research in genomic epidemiology (CHARGE) consortium. Circ Cardiovasc Genet 2010; 3:256-266.
41. Seifert JR, Mlodzik M. Frizzled/PCP signalling: a conserved mechanism regulating cell polarity and directed motility. Nat Rev Genet 2007; 8:126-138.
42. Bassuk AG, Wallace RH, Buhr A, Buller AR, Afawi Z, Shimojo M, et al. A homozygous mutation in human PRICKLE1 causes an autosomal-recessive progressive myoclonus epilepsy-ataxia syndrome. Am J Hum Genet 2008; 83:572-581.
43. Tao H, Manak JR, Sowers L, Mei X, Kiyonari H, Abe T, et al. Mutations in prickle orthologs cause seizures in flies, mice, and humans. Am J Hum Genet 2011; 88:138-149.
44. Fujimura L, Watanabe-Takano H, Sato Y, Tokuhisa T, Hatano M. Prickle promotes neurite outgrowth via the Dishevelled dependent pathway in C1300 cells. Neurosci Lett 2009; 467:6-10.
45. Lawes CM, Bennett DA, Feigin VL, Rodgers A. Blood pressure and stroke: an overview of published reviews. Stroke 2004; 35:1024.
46. Roush GC, Buddharaju V, Ernst ME, Holford TR. Chlorthalidone: mechanisms of action and effect on cardiovascular events. Curr Hypertens Rep 2013; 15:514-521.
47. Khoury MJ, Flanders WD. Nontraditional epidemiologic approaches in the analysis of gene-environment interaction: case-control studies with no controls! Am J Epidemiol 1996; 144:207-213.